search
Back to results

Study of Home-Based Resistance and Strength Training in HIV-Infected Women

Primary Purpose

HIV Infections

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Progressive resistance and aerobic training
Sponsored by
Massachusetts General Hospital
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for HIV Infections

Eligibility Criteria

18 Years - 60 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Subjects with documented HIV infection, by Western blot or ELISA Ages 18-60 Self-report AND physical evidence, as assessed by the investigators, of at least one of the following: increased abdominal girth; relative loss of fat in the face; relative loss of fat in the extremities; *dorsocervical fat pad; relative increased breast size; a score greater than or equal to 1.5 on the Lipodystrophy Scale and a waist to hip ratio of greater than or equal to 0.85. Exclusion Criteria: Pregnant or actively seeking pregnancy Breastfeeding New opportunistic infection diagnosed within 4 weeks of the study Pharmacologic glucocorticoid therapy (> 7.5 mg Prednisone or its equivalent/day) Androgen, growth hormone or Megace within 3 months of study initiation New anti-retroviral therapy within 1 month of the study SGOT > 5x normal and/or clinically significant liver disease Creatinine > 2.0 mg/dL and/or clinically significant renal disease Hemoglobin (Hgb) < 8.0g/dL Active substance abuse

Sites / Locations

  • Mass General Hospital

Outcomes

Primary Outcome Measures

aerobic fitness

Secondary Outcome Measures

strength
body composition
lipids
glucose
cardiovascular disease (CVD) risk markers

Full Information

First Posted
May 19, 2005
Last Updated
April 12, 2010
Sponsor
Massachusetts General Hospital
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
search

1. Study Identification

Unique Protocol Identification Number
NCT00111332
Brief Title
Study of Home-Based Resistance and Strength Training in HIV-Infected Women
Official Title
Exercise Effects in HIV-Infected Women
Study Type
Interventional

2. Study Status

Record Verification Date
April 2010
Overall Recruitment Status
Completed
Study Start Date
November 2002 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
July 2005 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Massachusetts General Hospital
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

4. Oversight

5. Study Description

Brief Summary
Lipodystrophy is characterized by increased cardiovascular disease. Limited strategies are available to increase cardiovascular fitness in this population, particularly among women. Progressive aerobic and resistance training will increase aerobic capacity and improve strength in HIV positive women with lipodystrophy.
Detailed Description
Baseline Testing: Eligible patients will be tested at the General Clinical Research Center (GCRC) of Massachusetts General Hospital or at the GCRC at Massachusetts Institute of Technology (MIT). For women with regular menses, the admission will correspond to the early follicular phase. Patients will receive a menstrual history calendar to submit at the baseline and 16 week visits. A complete history and physical exam will be performed, including a detailed history of all drugs being used in the treatment of the HIV disease or any associated conditions. Weight will be measured and expressed as a percentage of ideal body weight (IBW) and body mass index. Blood will be sampled to determine hormonal function (testosterone, free testosterone, SHBG, estradiol, LH, and FSH), nutritional status (albumin, prealbumin), lipid parameters (HDL, LDL, cholesterol, triglycerides), immune function (CD4, viral load, CBC), and thrombolytic markers (t-PA, PAI-1). An HIV test will be performed at the baseline visit only, in order to document patient status. Glucose homeostasis will be measured with the use of fasting glucose and insulin levels and an oral glucose tolerance test (OGTT). Heart rate will be monitored to test cardiovascular function. A spot urine will be collected for bone markers and beta-human chorionic gonadotropin (bHCG). Lean body mass and fat mass will be determined by a dual energy x-ray absorptiometry [DEXA] (to be performed at the MIT CRC); total body water will be determined by bioimpedance analysis; muscle cross-sectional area will be determined by anthropometric measurements. A quantitative computed tomography (CT) scan of the thigh and abdomen will be done to measure visceral and subcutaneous fat. A Magnetic Resonance Spectroscopy of calf muscles for determination of lipid concentrations in skeletal muscle will be done. (Subjects with contraindications to magnetic resonance imaging [MRI] will be able to remain in the protocol, but the MR-Spectroscopy will not be performed). A complete dietary assessment and resting energy expenditure will be performed. Quality of life will be assessed using the MOS HIV questionnaire and an activity questionnaire as well as the Karnofsky performance assessment. A submaximal exercise bicycle test will be done to assess aerobic capability, and a 6 minute walk test, sit to stand and get up and go tests will be done to assess overall functional status by the physical therapy (PT) department. Those who are not randomized to exercise at the baseline visit, will have one repetition maximum (1 RM) testing. The 1 RM is defined as the maximal amount of weight that can be lifted throughout full range of motion. The 1 RM will be tested by performing exercises including calf raises, arm curls, lateral raises, knee flexors, bench press and half squats. The 1 RM testing will be repeated on those who are not randomized to exercise at the 8 and 16 week visits. After the baseline investigation is over, subjects will be randomized into one of two groups (exercise or no exercise) for 16 weeks. Strength training will be performed using standard free weights under the supervision of a trained physical therapist or member of the study staff. Each session begins with a 5 minute warm-up and a standard flexibility routine. The strength training routine will follow and will focus on the following muscle groups: knee extensors and hip extensors, ankle plantar flexors, elbow flexors, pectoralis and shoulder abduction. The aerobic training program will follow the general guidelines established by the American College of Sports Medicine. Training will be performed using a standard stationery bicycle. Aerobic/endurance exercise will be performed with large muscle groups. The duration of the aerobic component of the training session will be 20 minutes during the first two weeks and 30 minutes thereafter. The intensity of the exercise will be 60% of maximal heart rate during the first two weeks and 75% thereafter. As the weeks progress, the repetitions and intensity of the exercise will be gradually increased. Subjects return to the GCRC at 8 weeks for a medical history, a physical exam, weight, and pregnancy test. Subjects return again at 16 weeks for a visit identical to that at baseline.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (false)

8. Arms, Groups, and Interventions

Intervention Type
Behavioral
Intervention Name(s)
Progressive resistance and aerobic training
Primary Outcome Measure Information:
Title
aerobic fitness
Secondary Outcome Measure Information:
Title
strength
Title
body composition
Title
lipids
Title
glucose
Title
cardiovascular disease (CVD) risk markers

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects with documented HIV infection, by Western blot or ELISA Ages 18-60 Self-report AND physical evidence, as assessed by the investigators, of at least one of the following: increased abdominal girth; relative loss of fat in the face; relative loss of fat in the extremities; *dorsocervical fat pad; relative increased breast size; a score greater than or equal to 1.5 on the Lipodystrophy Scale and a waist to hip ratio of greater than or equal to 0.85. Exclusion Criteria: Pregnant or actively seeking pregnancy Breastfeeding New opportunistic infection diagnosed within 4 weeks of the study Pharmacologic glucocorticoid therapy (> 7.5 mg Prednisone or its equivalent/day) Androgen, growth hormone or Megace within 3 months of study initiation New anti-retroviral therapy within 1 month of the study SGOT > 5x normal and/or clinically significant liver disease Creatinine > 2.0 mg/dL and/or clinically significant renal disease Hemoglobin (Hgb) < 8.0g/dL Active substance abuse
Facility Information:
Facility Name
Mass General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
16772251
Citation
Dolan SE, Frontera W, Librizzi J, Ljungquist K, Juan S, Dorman R, Cole ME, Kanter JR, Grinspoon S. Effects of a supervised home-based aerobic and progressive resistance training regimen in women infected with human immunodeficiency virus: a randomized trial. Arch Intern Med. 2006 Jun 12;166(11):1225-31. doi: 10.1001/archinte.166.11.1225.
Results Reference
background

Learn more about this trial

Study of Home-Based Resistance and Strength Training in HIV-Infected Women

We'll reach out to this number within 24 hrs